Antiresorptive therapy significantly reduces fracture risk in patients with benign bone disease and skeletal-related events (SREs) in patients with bone metastases (BM). Osteonecrosis of the jaw (ONJ) is a rare but severe condition manifested as necrotic bone lesion or lesions of the jaws. ONJ has been linked to the use of potent antiresorptive agents, termed medication-related ONJ (MRONJ).
Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases. a critical review organized by the ECTS / Anastasilakis, Athanasios D; Pepe, Jessica; Napoli, Nicola; Palermo, Andrea; Magopoulos, Christos; Khan, Aliya A; Zillikens, M Carola; Body, Jean-Jacques. - In: THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. - ISSN 1945-7197. - 107:5(2022), pp. 1441-1460. [10.1210/clinem/dgab888]
Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases. a critical review organized by the ECTS
Pepe, Jessica;
2022
Abstract
Antiresorptive therapy significantly reduces fracture risk in patients with benign bone disease and skeletal-related events (SREs) in patients with bone metastases (BM). Osteonecrosis of the jaw (ONJ) is a rare but severe condition manifested as necrotic bone lesion or lesions of the jaws. ONJ has been linked to the use of potent antiresorptive agents, termed medication-related ONJ (MRONJ).| File | Dimensione | Formato | |
|---|---|---|---|
|
Anastasilakis_Osteonecrosis_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.87 MB
Formato
Adobe PDF
|
1.87 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
